zanubrutinib

Zanubrutinib is an oral, irreversible, highly selective Bruton’s tyrosine kinase (BTK) inhibitor (IC₅₀ = 0.3 nM). This agent is used in research on tumors such as lymphoma and leukemia.

(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).

(±)-Zanubrutinib ((±)-BGB-3111) is a potent, orally available Bruton's tyrosine kinase (Btk) inhibitor, exhibiting superior oral bioavailability, higher exposure, and more complete target inhibition.

Zanubrutinib-D5 (Standard) is a reference standard of Zanubrutinib-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Zanubrutinib-d5 (BGB-3111-d5), a deuterium-labeled Zanubrutinib, is an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.

Zanubrutinib-D5, a deuterium-labeled Zanubrutinib (T7584), is an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.

zanubrutinib (Standard) is a reference standard for research and analysis in studies involving zanubrutinib. Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).